|
Groups
|
Number of studies
|
Number of participants
|
Fixed effects risk ratio(95% CI*)
|
Random effects risk ratio(95% CI)
|
Heterogeneity Chi 2( p)
|
|---|
|
All studies
|
8
|
10,320
|
0.65(0.47,0.89)#
|
0.53(0.38,0.80)
|
18.56(0.00968)
|
|
High quality
|
6
|
7,845
|
0.66(0.45,0.98)
|
0.55(0.35,0.87)
|
17.55(0.00357)
|
|
Low quality
|
2
|
2,474
|
0.53(0.30,0.94)
|
NA
|
0.47(0.49303)
|
|
HIV negative
|
6
|
9,509
|
0.55(0.40,0.75)
|
0.52(0.36,0.75)
|
8.57(0.1277)
|
|
HIV positive
|
2
|
810
|
0.86(0.41,1.81)
|
0.58(0.17,1.94)
|
5.14(0.02335)
|
|
TB endemic
|
5
|
2,189
|
0.78(0.55,1.11)
|
0.67(0.45,0.99)
|
8.93(0.06281)
|
|
TB non endemic
|
3
|
8,130
|
0.40(0.27,0.57)
|
NA
|
0.05(0.9736)
|
|
Primary TB prophylaxis
|
2
|
1,353
|
0.93(0.71,1.21)
|
NA
|
0.23(0.63119)
|
|
Secondary TB prophylaxis
|
3
|
5,224
|
0.44(0.31,0.61)
|
NA
|
1.05(0.59104)
|
|
Excluding studies INH was initiated at age ≤4 months
|
6
|
8,966
|
0.41(0.31,0.55)
|
NA
|
1.84(0.87086)
|
|
High quality excluding studies INH was initiated at age ≤4 months
|
4
|
6,492
|
0.38(0.27.0.53)
|
NA
|
0.43(0.93385)
|
|
INH initiated at age ≤4 months
|
2
|
1,353
|
0.93(0.71,1.21)
|
NA
|
0.23(0.29)
|
|
Age <5 years
|
3
|
1,616
|
0.86(0.57,1.30)
|
0.77(0.48,1.23)
|
5.14(0.07644)
|
|
Age 5–15 years
|
2
|
2,474
|
0.53(0.30,0.94)
|
NA
|
0.47(0.49303)
|
|
INH for ≥6 months
|
6
|
7,845
|
0.66(0.45,0.98)
|
0.55(0.35,0.87)
|
17.55(0.00357)
|
|
INH for <6 months
|
2
|
2,474
|
0.53(0.30,0.94)
|
NA
|
0.47(0.49303)
|
- *Adjusted for heterogeneity when appropriate.
-
#1 minus the risk ratio gives the protective effect, e.g. for the first row, 0.65 corresponds to 35% protection.
